MiNK Therapeutics, Inc. Net Fee Amt
MiNK Therapeutics, Inc. (INKT) had Net Fee Amt of $365.59 as of 2026-08-13, per its S-8 filed 2026-08-13.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-13
- 2026-08-13: Net Fee Amt $365.59.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-13 | $365.59 S-8 · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |